Clearance of Alzheimer’s amyloid-β1-40 peptide from brain by LDL receptor–related protein-1 at the blood-brain barrier
Open accessThe DOI matches its Crossref record; 77 of the 77 references it cites were found in a registry or an index; 16 of the 62 sources its claims cite were checked for support.
Abstract
Elimination of amyloid-ss peptide (Ass) from the brain is poorly understood. After intracerebral microinjections in young mice, (125)I-Ass(1-40) was rapidly removed from the brain (t(1/2) </= 25 minutes), mainly by vascular transport across the blood-brain barrier (BBB). The efflux transport system for Ass(1-40) at the BBB was half saturated at 15.3 nM, and the maximal transport capacity was reached between 70 nM and 100 nM. Ass(1-40) clearance was substantially inhibited by the receptor-associated protein, and by antibodies against LDL receptor-related protein-1 (LRP-1) and alpha(2)-macroglobulin (alpha(2)M). As compared to adult wild-type mice, clearance was significantly reduced in young and old apolipoprotein E (apoE) knockout mice, and in old wild-type mice. There was no evidence that Ass was metabolized in brain interstitial fluid and degraded to smaller peptide fragments and amino acids before its transport across the BBB into the circulation. LRP-1, although abundant in brain microvessels in young mice, was downregulated in older animals, and this downregulation correlated with regional Ass accumulation in brains of Alzheimer's disease (AD) patients. We conclude that the BBB removes Ass from the brain largely via age-dependent, LRP-1-mediated transport that is influenced by alpha(2)M and/or apoE, and may be impaired in AD.
Overview
CoChat Summary
TL;DR
In mice, intracerebrally injected ¹²⁵I-Aβ1-40 is rapidly cleared from brain, mainly by LRP-1-mediated transport across the blood-brain barrier, with clearance influenced by α2M and apoE. LRP-1 downregulation in older mice and in Alzheimer’s disease brain regions correlates with Aβ accumulation, suggesting impaired vascular clearance may contribute to AD.
Key findings
- After intracerebral microinjection in young mice, total brain efflux half-time for ¹²⁵I-Aβ1-40 was 25.5 ± 2.0 minutes versus 239.0 ± 12.5 minutes for [¹⁴C]inulin (9.4-fold difference); BBB transport accounted for 73.8% of efflux, ISF bulk flow 10.7%, and 15.6% remained retained at 60 nM.
- Aβ1-40 clearance was concentration-dependent, half-saturated at 15.3 nM, and maximal between 70 nM and 100 nM. Anti-LRP-1 antibody inhibited clearance by about 55% (58% at 12 nM and 53% at 60 nM), RAP inhibited by 30–44%, and anti-α2M inhibited by 25%; anti-LRP-2 and anti-RAGE had no effect.
- There was no evidence of significant Aβ1-40 degradation in brain ISF before transport: injected peptide was >97% intact, 93.7% remained intact at 60 minutes, and only 4.2–9.9% of brain ¹²⁵I radioactivity was non-TCA-precipitable within 270 minutes; plasma degradation increased from 37.6% to 58.3% between 15 and 120 minutes.
- Clearance was reduced in apoE knockout and older mice: 30% reduction in young apoE KO mice, about 55% and 40% reductions in 9-month-old wild-type and apoE KO mice at 12 nM, and 46% reduction in 9-month-old apoE KO mice at 60 nM. LRP-1-positive brain vessels dropped from 94% in 2-month-old mice to 52% in 9-month-old mice, and reduced LRP-1 staining in AD frontal cortex correlated with regional Aβ accumulation.
Methods
- Male C57BL/6 wild-type and apoE knockout mice at 8–10 weeks and 9–10 months received intracerebral microinjections into the right caudate nucleus of ¹²⁵I-Aβ1-40 (0.05–120 nM) plus [¹⁴C]inulin; clearance was measured from 10 to 300 minutes, with dose and inhibitor studies at 30 minutes.
- Radioactivity was analyzed by TCA precipitation, HPLC, and SDS-PAGE; compartmental modeling separated BBB transport, ISF bulk flow, and brain retention. Inhibitors included anti-LRP-1 R777, RAP, anti-α2M, anti-LRP-2, anti-RAGE, fucoidin, and BCH.
- Immunocytochemistry was performed in mouse brain and human frontal cortex/cerebellum from 3 AD patients and 3 age-matched controls (postmortem 4–7 hours), using antibodies against LRP-1, α2M, Aβ1-40/1-42, and CD105.
Limitations
- The paper does not state limitations explicitly. Evident from the text: the mouse clearance model uses synthetic ¹²⁵I-Aβ1-40 and intracerebral injection, which may not fully reflect endogenous Aβ production and clearance.
- Evident: human data are correlational and based on only 3 AD patients and 3 controls; LRP-1 involvement is inferred from antibody/RAP inhibition and immunostaining rather than direct transport assays.
- Evident: the identity of an alternative low-concentration BBB transport mechanism remains unknown, α2M staining cannot distinguish circulating from microvessel-associated α2M, and age comparisons are limited to young versus 9-month-old mice.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
12 Valid · 0 Not valid · 21 Not checked · 114 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Previous studies from our laboratory and others have demonstrated a major role of the BBB in determining the concentrations of A b in the CNS by regulating transport of circulating A b (33, 39, 49-51, 62-66).”
What the sources say
- Partly supportedcites [33] Mackic, 1998, J Clin Invest sourceExperimental — accuracy not yet measured
The Discussion reports transport of circulating Aβ across a human BBB cell model and says that this transport would tend to increase Aβ accumulation in the brain. It does not demonstrate that the BBB has a major role in determining CNS Aβ concentrations in vivo; the paper describes that broader implication as likely. Page numbers are unavailable in our copy. (LLM, conf=0.84)
- Partly supportedcites [39] Zlokovic, 1996, Proc Natl Acad Sci USA sourceExperimental — accuracy not yet measured
The paper’s opening summary (page not specified in our copy) reports transport of Aβ–apolipoprotein J complexes across the blood–brain barrier into brain tissue in a guinea pig model. It does not establish that this transport has a major role in determining overall CNS Aβ concentrations, as the citing sentence claims. (LLM, conf=0.84)
- Not checked — no full text of the sourcecites [49] Maness, 1994, Life Sci source
- Not checked — no full text of the sourcecites [50] Poduslo, 1997, Neurobiol Dis source
- Not checked — no full text of the sourcecites [51] Martel, 1997, J Neurochem source
boostedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Binding/uptake studies in mouse embryonic fibroblasts (wild type and deficient in LRP-1), confirmed that free A b is not a ligand for LRP-1 (37, 45).”
What the sources say
- Partly supportedcites [37] Narita, 1997, J Neurochem sourceExperimental — accuracy not yet measured
The Abstract and Discussion report that free Aβ degradation was not inhibited by RAP and describe it as LRP-independent. But Table 1 tested free Aβ in human U87 glioblastoma cells; the mouse embryonic fibroblast comparison tested Aβ complexed with α2-macroglobulin, not free Aβ. Thus the paper supports the LRP-independent uptake conclusion, but not the claim that the fibroblast studies confirmed it. (LLM, conf=0.87)
- Not checked — no full text of the sourcecites [45] Kounnas, 1995, Cell source
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Because normal aging is associated with A b accumulation in the brain (1)”
What the sources say
- Supportedcites [1] Wisniewski, 1997, Neurobiol Dis source
The section on the amyloid cascade hypothesis says that extensive Aβ-containing preamyloid deposits can be found in aged individuals with no reported clinical symptoms. This supports the claim that brain Aβ accumulation is associated with normal aging; the paper does not say it occurs in every older person. (LLM, conf=0.88)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“This makes re-entry of radiolabeled A b into the brain very unlikely, because the blood-to-brain transport of A b normally operates down the concentration gradient (39, 62-65).”
What the sources say
- Partly supportedcites [39] Zlokovic, 1996, Proc Natl Acad Sci USA sourceExperimental — accuracy not yet measured
The paper’s study summary (page not identified in our copy) reports transport of Aβ–apolipoprotein J complexes from blood into brain parenchyma. It does not say that this transport normally follows a concentration gradient or that re-entry of radiolabeled Aβ is unlikely. (LLM, conf=0.78)
- Not checked — no full text of the sourcecites [62] Zlokovic, 1993, Biochem Biophys Res Commun source
- Not checked — no full text of the sourcecites [63] Ghilardi, 1996, Neuroreport source
- Not checked — no full text of the sourcecites [64] Shayo, 1997, Life Sci source
- Partly supportedcites [65] Martel, 1996, Neurosci Lett sourceExperimental — accuracy not yet measured
The discussion passage in our copy (labeled Abstract; page unavailable) says that a lower soluble Aβ42 concentration on the brain side of the BBB would provide a thermodynamic impetus for transport from capillaries into brain. It does not establish that blood-to-brain transport normally operates down a concentration gradient or that re-entry of radiolabeled Aβ is very unlikely; the study also observed uptake of radiolabeled Aβ in perfused guinea-pig brains. (LLM, conf=0.80)
hedgedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“RAP, a chaperone protein that facilitates proper folding and subsequent trafficking of LRP-1 and LRP-2 (69), also inhibited A b clearance.”
What the sources say
- Partly supportedcites [69] Bu, 1996, J Biol Chem sourceExperimental — accuracy not yet measured
The citation is attached to the description of RAP as a folding and trafficking chaperone, not to the citing authors’ statement that RAP inhibited Aβ clearance. The paper’s Discussion supports that role for LRP, but does not establish it for the separate receptor LRP-2; its use of “LRP2” denotes a domain of LRP. (LLM, conf=0.89)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
92 more claims
Create a free account to see all 147 claims and to verify the 1 reference still open.
- It may state two separate claims as one. 30
- Probably not a substantial claim. 25
- The quote only partly states this claim. 2
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“For example, transport studies using radiolabeled and unlabeled Alzheimer's A 𝛃 peptide have shown that under physiological conditions, the perivascular ISF flow contributes to 15-20% of A 𝛃 clearance from the mouse brain (58, 535, 659), whereas 8085% is removed by transvascular BBB transport.”
From Blood-Brain Barrier: From Physiology to Disease and Back (2019) · cites this paper as [535]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“LRP1 binds Alzheimer's A 𝛃 toxin and mediates its brain-to-blood clearance (58, 137, 535, 561).”
From Blood-Brain Barrier: From Physiology to Disease and Back (2019) · cites this paper as [535]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Several groups have reported that trans-BBB efflux of Aβ into peripheral blood circulation is one of the main pathways of physiological clearance with ApoE, ApoJ, and ApoA1 as chaperones27,31,32.”
From Brain-targeted drug delivery by manipulating protein corona functions (2019) · cites this paper as [27]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“LRP1 and LRP2 are expressed in brain endothelium and colocalize mainly on the abluminal side of the BBB in humans and rodents (137, 404, 535, 607, 682).”
From Blood-Brain Barrier: From Physiology to Disease and Back (2019) · cites this paper as [535]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“whereas 8085% is removed by transvascular BBB transport.”
From Blood-Brain Barrier: From Physiology to Disease and Back (2019) · cites this paper as [535]
Experimental — accuracy not yet measured
25 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Results · p. 5
“The HPLC analysis of brain radioactivity confirmed the TCA results by indicating that 93.7% of the peptide remains intact in brain ISF at 60 minutes (Figure 3b, right).”
§ Figure 3 · p. 6
“( b ) Left panel shows HPLC elution profile of brain tissue 60 minutes after intracerebral microinjection of 125 I-A b 1-40 (60 nM). Separation was performed for 30 mg of brain tissue on a reverse-phase HPLC column, using a 30-minute linear gradient of 25-83% acetonitrile in 0.1% TFA, pH 2. 125 I-A b 1-40 eluted at 52%, corresponding to the elution time of A b 1-40 standard. Right panel shows SDS-PAGE analysis”
Citations
Cites
Amyloid plaque core protein in Alzheimer disease and Down syndrome.
Masters, C. L., Simms, G., Weinman, N. A., Multhaup, G., McDonald, B. L., & Beyreuther, K. (1985) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.82.12.4245 · Cited by 4,431 · cited 10×
“No anti-Aβ1-40–positive or Aβ1-42–positive staining was seen in either AD or control tissues.”
BackgroundInfluentialCorrelative Memory Deficits, Aβ Elevation, and Amyloid Plaques in Transgenic Mice
Hsiao, K., Chapman, P., Nilsen, S., Eckman, C., Harigaya, Y., Younkin, S., Yang, F., & Cole, G. (1996) · Science · doi:10.1126/science.274.5284.99 · Cited by 4,210 · cited 2×
“Because normal aging is associated with Aβ accumulation in the brain (1), and there is a significant, timedependent, and progressive accumulation of the peptide with age in transgenic APP animals (54, 55), we postulated that Aβ clearance mechanisms might be impaired in older animals, and are also possibly impaired in…”
BackgroundRAGE and amyloid-β peptide neurotoxicity in Alzheimer's disease
Yan, S. D., Chen, X., Fu, J., Chen, M., Zhu, H., Roher, A., Slattery, T., Zhao, L., Nagashima, M., Morser, J., et al. (1996) · Nature · doi:10.1038/382685a0 · Cited by 2,012 · cited 9×
“In contrast, anti–LRP-2 Ab (Figure 4b) and anti-RAGE Ab (Figure 4c) did not affect Aβ clearance.”
BackgroundInfluentialIsolation and quantification of soluble Alzheimer's β-peptide from biological fluids
Seubert, P., Vigo-Pelfrey, C., Esch, F., Lee, M., Dovey, H., Davis, D., Sinha, S., Schiossmacher, M., Whaley, J., Swindlehurst, C., et al. (1992) · Nature · doi:10.1038/359325a0 · Cited by 1,731
HYMAN, B. T., & TROJANOWSKI, J. Q. (1997) · Journal of Neuropathology and Experimental Neurology · doi:10.1097/00005072-199710000-00002 · Cited by 1,542
Production of the Alzheimer Amyloid β Protein by Normal Proteolytic Processing
Shoji, M., Golde, T. E., Ghiso, J., Cheung, T. T., Estus, S., Shaffer, L. M., Cai, X.-D., McKay, D. M., Tintner, R., Frangione, B., et al. (1992) · Science · doi:10.1126/science.1439760 · Cited by 1,447 · cited 1×
“β-amyloid (1-42) is a major component of cere-”
BackgroundSelf-citationHolcomb, L., Gordon, M. N., McGowan, E., Yu, X., Benkovic, S., Jantzen, P., Wright, K., Saad, I., Mueller, R., Morgan, D., et al. (1998) · Nature Medicine · doi:10.1038/nm0198-097 · Cited by 1,386 · cited 1×
“Because normal aging is associated with Aβ accumulation in the brain (1), and there is a significant, timedependent, and progressive accumulation of the peptide with age in transgenic APP animals (54, 55), we postulated that Aβ clearance mechanisms might be impaired in older animals, and are also possibly impaired in…”
BackgroundAlzheimer's Disease--Genotypes, Phenotype, and Treatments
Selkoe, D. J. (1997) · Science · doi:10.1126/science.275.5300.630 · Cited by 875 · cited 1×
“β-amyloid (1-42) is a major component of cere-”
BackgroundIwata, N., Tsubuki, S., Takaki, Y., Watanabe, K., Sekiguchi, M., Hosoki, E., Kawashima-Morishima, M., Lee, H.-J., Hama, E., Sekine-Aizawa, Y., et al. (2000) · Nature Medicine · doi:10.1038/72237 · Cited by 867 · cited 8×
“However, the physiological relevance of the proposed degradation mechanism for Aβ1-42 (28) remains unclear, because the peptide was studied at extremely high concentrations (∼ 240 μM) that are not found even in brains with severe β-amyloidosis (30).”
BackgroundMethodResultInfluentialThe cell biology of β-amyloid precursor protein and presenilin in Alzheimer's disease
Selkoe, D. (1998) · Trends in Cell Biology · doi:10.1016/s0962-8924(98)01363-4 · Cited by 862 · cited 1×
“β-amyloid (1-42) is a major component of cere-”
Background
Research works printed but not linked: 4
- Suzuki, 1994, Am J Pathol, 145, 452
- Urmoneit, 1997, Lab Invest, 77, 157
- Yamada, 1991, Am J Physiol, 261, H1197
- Kounnas, 1994, In Vivo, 8, 343
Cited by
Items 401–500 of 1,448
He, J.-T., Zhao, X., Xu, L., & Mao, C.-Y. (2020) · Journal of Alzheimer’s Disease · doi:10.3233/jad-190764 · Cited by 84
Blood–brain barrier endothelial cells in neurodegenerative diseases: Signals from the “barrier”
Yuan, Y., Sun, J., Dong, Q., & Cui, M. (2023) · Frontiers in Neuroscience · doi:10.3389/fnins.2023.1047778 · Cited by 93
“The receptor for advanced glycation end products (RAGE) mediates the entry of circulating Aβ into the brain, while the low-density lipoprotein receptor-related protein 1 (LRP1) is involved in transporting the Aβ out of the brain (Shibata et al., 2000; Deane et al., 2003).”
BackgroundLoeffler, D. A. (2023) · Journal of Alzheimer's Disease Reports · doi:10.3233/adr-230025 · Cited by 79
“The expression of LRP1 on brain endothelial cells has been suggested to decrease during normal aging [101, 102] and in AD [103, 104], which could reduce the ability of antibodies to clear A from the brain via this mechanism.”
BackgroundContinuous CSF drainage in AD: Results of a double-blind, randomized, placebo-controlled study
Silverberg, G. D., Mayo, M., Saul, T., Fellmann, J., Carvalho, J., & McGuire, D. (2008) · Neurology · doi:10.1212/01.wnl.0000316197.04157.6f · Cited by 87
Modes of Aβ toxicity in Alzheimer’s disease
Götz, J., Eckert, A., Matamales, M., Ittner, L. M., & Liu, X. (2011) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-011-0750-2 · Cited by 83
Gali, C. C., Fanaee-Danesh, E., Zandl-Lang, M., Albrecher, N. M., Tam-Amersdorfer, C., Stracke, A., Sachdev, V., Reichmann, F., Sun, Y., Avdili, A., et al. (2019) · Molecular and Cellular Neuroscience · doi:10.1016/j.mcn.2019.103390 · Cited by 88
Clearance of two organic nanoparticles from the brain via the paravascular pathway
Gu, X., Song, Q., Zhang, Q., Huang, M., Zheng, M., Chen, J., Wei, D., Chen, J., Wei, X., Chen, H., et al. (2020) · Journal of Controlled Release · doi:10.1016/j.jconrel.2020.03.009 · Cited by 87
Apolipoprotein E, Amyloid-β, and Blood-Brain Barrier Permeability in Alzheimer Disease
Donahue, J. E., & Johanson, C. E. (2008) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0b013e31816a0dc8 · Cited by 86
“Two of the bettercharacterized receptors are the receptor for advanced glycation end-products (RAGE) (37) and the low-density LRP-1 (38).”
BackgroundWhy lipids are important for Alzheimer disease?
Hirsch-Reinshagen, V., Burgess, B. L., & Wellington, C. L. (2009) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-008-0012-2 · Cited by 86
Qi, X.-M., & Ma, J. (2017) · Translational Neurodegeneration · doi:10.1186/s40035-017-0091-7 · Cited by 93
“the Aβ efflux through BBB and further elimination by the liver, spleen and kidney [47].”
BackgroundIto, S., Ohtsuki, S., Kamiie, J., Nezu, Y., & Terasaki, T. (2007) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2007.04938.x · Cited by 85
“We and others have used different cerebral microinjection techniques to investigate the role of LRP-1 in soluble human Ab(1–40) [hAb(1–40)] monomer elimination, for example by blocking LRP-1–ligand binding with RAP (Shibata et al. 2000; Deane et al. 2004; Shiiki et al. 2004; Ito et al. 2006).”
BackgroundMethodResultInfluentialInteractions between glial cells and the blood-brain barrier and their role in Alzheimer's disease
Zhao, M., Jiang, X., Zhang, H., Sun, J., Pei, H., Ma, L., Cao, Y., & Li, H. (2021) · Ageing Research Reviews · doi:10.1016/j.arr.2021.101483 · Cited by 99
The integrity of the blood?brain barrier in Alzheimer?s disease
Algotsson, A., & Winblad, B. (2007) · Acta Neurologica Scandinavica · doi:10.1111/j.1600-0404.2007.00823.x · Cited by 86
“It has been found that RAGE (receptor for advanced glycation end products) acts as an influx receptor (27) and that LRP 1 (lowdensity lipoprotein receptor-related protein1) (28) and Pgp (p-glycoprotein) (29) act as efflux receptors.”
Background(2012) · Progress in Molecular Biology and Translational Science · doi:10.1016/b978-0-12-385883-2.00006-0 · Cited by 84
Lee, S., Chu, K., Park, J., Jung, K., Jeon, D., Lim, J., Lee, S. K., Kim, M., & Roh, J. (2012) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2011.07534.x · Cited by 84
“Clearance of Ab in AD brain partly depends on the action of endothelial transporters, such as RAGE and low density lipoprotein receptor-related protein 1(Shibata et al. 2000; Yan et al. 1996).”
BackgroundAmyloid-beta and Alzheimer’s disease: the role of neprilysin-2 in amyloid-beta clearance
Marr, R. A., & Hafez, D. M. (2014) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2014.00187 · Cited by 83
“ApoE can affect Aβ in multiple ways including its aggregation, clearance, and catabolism (Bales et al., 1999; Holtzman et al., 2000; Shibata et al., 2000; Fagan et al., 2002; Dolev and Michaelson, 2004; Koistinaho et al., 2004; Manelli et al., 2004; Dodart et al., 2005; Bu, 2009; Belinson et al.,…”
Differential modulation of plasma β-amyloid by insulin in patients with Alzheimer disease
Kulstad, J. J., Green, P. S., Cook, D. G., Watson, G. S., Reger, M. A., Baker, L. D., Plymate, S. R., Asthana, S., Rhoads, K., Mehta, P. D., et al. (2006) · Neurology · doi:10.1212/01.wnl.0000216274.58185.09 · Cited by 82
Ten Challenges of the Amyloid Hypothesis of Alzheimer’s Disease
Kepp, K. P. (2016) · Journal of Alzheimer's Disease · doi:10.3233/jad-160550 · Cited by 81
“[65] Shibata M, Yamada S, Kumar SR, Calero M, Bading J, Frangione B, Holtzman DM, Miller CA, Strickland DK, Ghiso J (2000) Clearance of Alzheimer’s amyloid-β 1-40”
Sagare, A. P., Deane, R., Zetterberg, H., Wallin, A., Blennow, K., & Zlokovic, B. V. (2011) · Journal of Alzheimer's Disease · doi:10.3233/jad-2010-101248 · Cited by 80
Yamada, S. (2014) · Croatian Medical Journal · doi:10.3325/cmj.2014.55.337 · Cited by 84
Self-citationTanaka, H., Nakatani, T., Furihata, T., Tange, K., Nakai, Y., Yoshioka, H., Harashima, H., & Akita, H. (2018) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.7b01084 · Cited by 82
Endothelial BACE1 Impairs Cerebral Small Vessels via Tight Junctions and eNOS
Zhou, H., Gao, F., Yang, X., Lin, T., Li, Z., Wang, Q., Yao, Y., Li, L., Ding, X., Shi, K., et al. (2022) · Circulation Research · doi:10.1161/circresaha.121.320183 · Cited by 88
Alzheimer culprits: Cellular crossroads and interplay
Claeysen, S., Cochet, M., Donneger, R., Dumuis, A., Bockaert, J., & Giannoni, P. (2012) · Cellular Signalling · doi:10.1016/j.cellsig.2012.05.008 · Cited by 96
Genetic evidence for the involvement of lipid metabolism in Alzheimer's disease
Jones, L., Harold, D. H., & Williams, J. H. (2010) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2010.04.005 · Cited by 91
Exosome Production Is Key to Neuronal Endosomal Pathway Integrity in Neurodegenerative Diseases
Mathews, P. M., & Levy, E. (2019) · Frontiers in Neuroscience · doi:10.3389/fnins.2019.01347 · Cited by 75
“Exosomes are unique in that their limiting membrane renders them more stable in the extracellular environment than is the case for secreted, soluble proteins (reviewed in Simpson et al., 2008).”
BackgroundDivecha, Y. A., Rampes, S., Tromp, S., Boyanova, S., Fleckney, A. L., Fidanboylu, M., & Thomas, S. A. (2025) · Pharmacological Reviews · doi:10.1016/j.pharmr.2025.100052 · Cited by 92
“…and clinical studies have shown that A b accumulation within the brain and AD pathology correlate with higher RAGE levels and lower LRP1 levels within the brain parenchyma (Shibata et al, 2000; Deane et al, 2004, 2012; Donahue et al, 2006; Zlokovic, 2008; Storck et al, 2015; Osgood et al, 2017).”
Therapeutic role of rifampicin in Alzheimer's disease
Yulug, B., Hanoglu, L., Ozansoy, M., Isık, D., Kilic, U., Kilic, E., & Schabitz, W. R. (2018) · Psychiatry and Clinical Neurosciences · doi:10.1111/pcn.12637 · Cited by 81
“It has already been demonstrated that low- density lipoprotein receptor-related protein 1 (LRP1) reveals a diverse modifying effect on amyloid trafficking in the brain.(27,28) Additionally, the efflux transporter permeability glycoprotein (P-gp), which is located on brain capillary endothelial cells in the BBB and bel…”
BackgroundUekawa, K., Hattori, Y., Ahn, S. J., Seo, J., Casey, N., Anfray, A., Zhou, P., Luo, W., Anrather, J., Park, L., et al. (2023) · Molecular Neurodegeneration · doi:10.1186/s13024-023-00660-1 · Cited by 80
“Therefore, the reduction in brain Aβ1–40 and CAA in CD36−/− → Tg2676 chimeras raises the possibility that CD36 deficiency promotes Aβ1–40 clearance [73] by counteracting the well-described neurovascular dysfunction induced by Aβ1–40.”
BackgroundLipid Metabolism and Glial Lipoproteins in the Central Nervous System
Hayashi, H. (2011) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.34.453 · Cited by 80
Bourassa, P., Tremblay, C., Schneider, J. A., Bennett, D. A., & Calon, F. (2019) · Acta Neuropathologica · doi:10.1007/s00401-019-01967-4 · Cited by 87
Age-Related Functional and Expressional Changes in Efflux Pathways at the Blood-Brain Barrier
Erdő, F., & Krajcsi, P. (2019) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2019.00196 · Cited by 76
“Lipoprotein receptor-related protein-1 (LRP-1) also contributes to brain efflux of amyloid-β (Aβ) peptide (Shibata et al., 2000).”
BackgroundGião, T., Saavedra, J., Cotrina, E. Y., Quintana, J. R., Llop, J., Arsequell, G., & Cardoso, I. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21062075 · Cited by 91
“Restoring the levels of these proteins, namely of LRP1, is usually studied via gene delivery, which is complex and raises safety issues.”
BackgroundInfluentialGold, B. T., Shao, X., Sudduth, T. L., Jicha, G. A., Wilcock, D. M., Seago, E. R., & Wang, D. J. J. (2021) · Alzheimer s & Dementia · doi:10.1002/alz.12357 · Cited by 88
Beta‐Amyloid Downregulates MDR1‐P‐Glycoprotein (Abcb1) Expression at the Blood‐Brain Barrier in Mice
Brenn, A., Grube, M., Peters, M., Fischer, A., Jedlitschky, G., Kroemer, H. K., Warzok, R. W., & Vogelgesang, S. (2011) · International Journal of Alzheimer’s Disease · doi:10.4061/2011/690121 · Cited by 74
Guan, H., Liu, Y., Daily, A., Police, S., Kim, M., Oddo, S., LaFerla, F. M., Pauly, J. R., Murphy, M. P., & Hersh, L. B. (2009) · Journal of Neuroscience Research · doi:10.1002/jnr.21944 · Cited by 81
“This would result in a decrease in peripheral vascular resistance and an increase in blood pressure (Shibata et al., 2000; Weber, 2001).”
BackgroundWang, H., Chen, F., Du, Y., Long, Y., Reed, M. N., Hu, M. Y., Suppiramaniam, V. D., Hong, H., & Tang, S. (2017) · Neuropharmacology · doi:10.1016/j.neuropharm.2017.12.026 · Cited by 84
Insulin-degrading Enzyme in Brain Microvessels
Morelli, L., Llovera, R. E., Mathov, I., Lue, L.-F., Frangione, B., Ghiso, J., & Castaño, E. M. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m407283200 · Cited by 76
Self-citationSystemic Amyloid Deposits in Familial British Dementia
Ghiso, J. A., Holton, J., Miravalle, L., Calero, M., Lashley, T., Vidal, R., Houlden, H., Wood, N., Neubert, T. A., Rostagno, A., et al. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m105956200 · Cited by 80
Self-citationBrenn, A., Grube, M., Jedlitschky, G., Fischer, A., Strohmeier, B., Eiden, M., Keller, M., Groschup, M. H., & Vogelgesang, S. (2014) · Brain Pathology · doi:10.1111/bpa.12069 · Cited by 79
“The clearance of Aβ from the brain into the blood at the BBB comprises a two-step mechanism involving the lowdensitiy lipoprotein receptor as a putative transcytosis mediator at the abluminal site of endothelial cells (27), and P-gp and possibly other ABC transporters at the luminal side.”
BackgroundInfluentialRole of clusterin in the brain vascular clearance of amyloid-β
Nelson, A. R., Sagare, A. P., & Zlokovic, B. V. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1711357114 · Cited by 80
Powering Amyloid Beta Degrading Enzymes: A Possible Therapy for Alzheimer’s Disease
Sikanyika, N. L., Parkington, H. C., Smith, A. I., & Kuruppu, S. (2019) · Neurochemical Research · doi:10.1007/s11064-019-02756-x · Cited by 84
Dutheil, F., Jacob, A., Dauchy, S., Beaune, P. H., Scherrmann, J., Declèves, X., & Loriot, M. (2010) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.2010.510832 · Cited by 79
“Ab peptides are transported across the BBB by receptor-mediated transcytosis: lowdensity lipoprotein receptor-related protein-1 is involved in the efflux of Ab peptides from the brain, whereas the receptor for advanced glycation end products is involved in shuttling Ab from the circulation into the brain [85,86].”
BackgroundYoon, I., Chen, E., Busse, T., Repetto, E., Lakshmana, M. K., Koo, E. H., & Kang, D. E. (2007) · The FASEB Journal · doi:10.1096/fj.07-8114com · Cited by 77
“Third, LRP plays a role in the removal of A complexed to 2-macroglobulin and apoE in cultured cells (26, 30, 31), as well as in brain efflux of A isoforms at the blood-brain barrier, supporting a model in which LRP plays an important role in extracellular A uptake and removal (32).”
BackgroundThe Possible Role of Antioxidant Vitamin C in Alzheimer’s Disease Treatment and Prevention
Heo, J.-H., Hyon-Lee, & Lee, K.-M. (2013) · American Journal of Alzheimer's Disease & Other Dementias® · doi:10.1177/1533317512473193 · Cited by 79
“The Ab immunotherapy, which is currently being actively pursued, also suggests that the efficacy of Ab clearance is determined by the levels of cell surface Ab receptors in the BBB. (4) The clinical impact of antioxidants including vitamin C on AD is yet to be firmly established.”
BackgroundPerrotta, M., Lembo, G., & Carnevale, D. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms17030347 · Cited by 86
“Interestingly, ApoE, one of the most important risk factors associated with AD and CAA, is an LRP-1 ligand and modulates the rate of Aβ transport [69].”
BackgroundVascular pathology: Cause or effect in Alzheimer disease?
Rius-Pérez, S., Tormos, A. M., Pérez, S., & Taléns-Visconti, R. (2018) · Neurología (English Edition) · doi:10.1016/j.nrleng.2015.07.008 · Cited by 75
Leal, M. C., Dorfman, V. B., Gamba, A. F., Frangione, B., Wisniewski, T., Castaño, E. M., Sigurdsson, E. M., & Morelli, L. (2006) · Journal of Neuropathology and Experimental Neurology · doi:10.1097/01.jnen.0000235853.70092.ba · Cited by 74
Self-citationUllah, R., Park, T. J., Huang, X., & Kim, M. O. (2021) · Ageing Research Reviews · doi:10.1016/j.arr.2021.101451 · Cited by 78
“In contrast, low-density lipoprotein receptor (LDLR) family members (such as LRP-1) mediate Aβ peptide efflux from the brain to circulating blood (periphery) and are considered one of the dominant Aβ peptide transport mediators via the BBB (Citron, 2010; Shibata et al., 2000).”
BackgroundBehl, T., Kaur, I., Sehgal, A., Kumar, A., Uddin, M. S., & BUNGAU, S. G. (2020) · Molecular Neurobiology · doi:10.1007/s12035-020-02211-x · Cited by 84
Candela, P., Saint‐Pol, J., Kuntz, M., Boucau, M., Lamartinière, Y., Gosselet, F., & Fénart, L. (2014) · Brain Research · doi:10.1016/j.brainres.2014.10.047 · Cited by 87
Insights into the pathogenesis and pathogenicity of cerebral amyloid angiopathy
Love, S. (2009) · Frontiers in Bioscience · doi:10.2741/3567 · Cited by 75
Henderson, S. J., Andersson, C., Narwal, R., Janson, J., Goldschmidt, T. J., Appelkvist, P., Bogstedt, A., Steffen, A.-C., Haupts, U., Tebbe, J., et al. (2014) · Brain · doi:10.1093/brain/awt308 · Cited by 77
“receptor related protein-1 (LRP1) (Shibata et al., 2000).”
BackgroundNew Therapeutic Approaches for Alzheimer’s Disease and Cerebral Amyloid Angiopathy
Saito, S., & Ihara, M. (2014) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2014.00290 · Cited by 73
“The relationship is further supported by reduced LRP-1 staining in vessels both in AD patients (Shibata et al., 2000; Donahue et al., 2006) and CAA model mice carrying a vasculotropic Dutch/Iowa mutant form of APP gene (Deane et al., 2004).”
BackgroundInfluentialNaert, G., & Rivest, S. (2012) · Molecular Medicine · doi:10.2119/molmed.2011.00306 · Cited by 76
Shen, J., Zhan, C., Xie, C., Meng, Q., Gu, B., Li, C., Zhang, Y., & Lu, W. (2010) · Journal of drug targeting · doi:10.3109/1061186x.2010.483517 · Cited by 79
“The failure of brain drug delivery is due to the barrier properties of blood-brain barrier (BBB) formed by brain microvessel endothelial cells with tight junctions and low pinocytic activity, which maintains the homeostatic function of the brain and restricts the transfer of many potentially therapeutic agents from th…”
BackgroundInfluentialPrasansuklab, A., & Tencomnao, T. (2013) · Evidence-Based Complementary and Alternative Medicine · doi:10.1155/2013/413808 · Cited by 75
Cerebral Amyloid Angiopathy: A Common Cause of Cerebral Hemorrhage
Pezzini, A., Del Zotto, E., Volonghi, I., Giossi, A., Costa, P., & Padovani, A. (2009) · Current Medicinal Chemistry · doi:10.2174/092986709788682047 · Cited by 76
“Second, LRP-1, although abundant in brain microvessels (including capillaries, arterioles, and small venules) in young mice and humans, is downregulated in older animals and AD brain [85].”
InfluentialSignaling Mechanisms of Selective PPAR γ Modulators in Alzheimer’s Disease
Govindarajulu, M., Pinky, P. D., Bloemer, J., Ghanei, N., Suppiramaniam, V., & Amin, R. (2018) · PPAR Research · doi:10.1155/2018/2010675 · Cited by 73
“P-glycoprotein localized predominantly on the abluminal side of the cerebral endothelium [77, 78].”
BackgroundJeon, M.-T., Kim, K.-S., Kim, E. S., Lee, S., Kim, J., Hoe, H.-S., & Kim, D.-G. (2021) · Ageing Research Reviews · doi:10.1016/j.arr.2021.101333 · Cited by 76
“15 Another transporter, low-density lipoprotein receptor-related protein 1 (LRP1), is associated with Aβ clearance from the brain to blood across the BBB (Shibata et al., 2000).”
BackgroundParodi-Rullán, R. M., Javadov, S., & Fossati, S. (2021) · Cells · doi:10.3390/cells10112903 · Cited by 73
“Expression of RAGE in microglia of transgenic mice expressing a mutant human APP, induced IL-1β and TNFα production [92].”
BackgroundInfluentialTransport characteristics of a novel peptide platform for CNS therapeutics
Bertrand, Y., Currie, J.-C., Demeule, M., Régina, A., Ché, C., Abulrob, A., Fatehi, D., Sartelet, H., Gabathuler, R., Castaigne, J., et al. (2009) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2009.00930.x · Cited by 85
“Additionally, LRP-1, which participates in transporting Angiopep-2 across the BBB, is abundantly expressed on brain capillaries [26, 27].”
BackgroundBasal lamina changes in neurodegenerative disorders
Nguyen, B., Bix, G., & Yao, Y. (2021) · Molecular Neurodegeneration · doi:10.1186/s13024-021-00502-y · Cited by 75
“Similarly, activation of the same pathway in pericytes causes BBB breakdown in mice deficient in murine ApoE or those expressing human ApoE4, which poorly interacts with LRP1 [104].”
BackgroundInfluentialYan, L., Xie, Y., Satyanarayanan, S. K., Zeng, H., Liu, Q., Huang, M., Ma, Y., Wan, J., Yao, X., Su, K., et al. (2019) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2019.05.033 · Cited by 80
The effect of aquaporin-4 mis-localization on Aβ deposition in mice
Pedersen, T. J., Keil, S. A., Han, W., Wang, M. X., & Iliff, J. J. (2023) · Neurobiology of Disease · doi:10.1016/j.nbd.2023.106100 · Cited by 84
“Several mechanisms have been implicated in the process of Aclearance, including local cellular degradation(Ries and Sastre, 2016), transporter-mediated transendothelial efflux,(Deane et al., 2003; Shibata et al., 2000) clearance along perivascular spaces surrounding and within the mural wall of penetrating arteries…”
BackgroundEnvironmental Enrichment Counteracts Alzheimer’s Neurovascular Dysfunction in TgCRND8 Mice
Herring, A., Yasin, H., Ambrée, O., Sachser, N., Paulus, W., & Keyvani, K. (2008) · Brain Pathology · doi:10.1111/j.1750-3639.2007.00094.x · Cited by 73
Eggert, S., Thomas, C., Kins, S., & Hermey, G. (2018) · Molecular Neurobiology · doi:10.1007/s12035-017-0806-x · Cited by 81
Aβ42 production in brain capillary endothelial cells after oxygen and glucose deprivation
Bulbarelli, A., Lonati, E., Brambilla, A., Orlando, A., Cazzaniga, E., Piazza, F., Ferrarese, C., Masserini, M., & Sancini, G. (2012) · Molecular and Cellular Neuroscience · doi:10.1016/j.mcn.2012.01.007 · Cited by 82
“Indeed, both the hypotheses for Aβ42 passage via the BBB, such as receptor mediated transport or BBB leakage caused by Aβ42 toxicity, were demonstrated (Jancsó et al., 1998; Pluta et al., 1996; Poduslo et al., 1999; Strazielle et al., 2000; Zlokovic, 1996).”
BackgroundInfluentialLipid nanocapsules to enhance drug bioavailability to the central nervous system
Moura, R. P., Pacheco, C., Pêgo, A. P., Rieux, A. D., & Sarmento, B. F. C. C. (2020) · Journal of Controlled Release · doi:10.1016/j.jconrel.2020.03.042 · Cited by 75
Youn, K., Ho, C., & Jun, M. (2022) · Food Science and Human Wellness · doi:10.1016/j.fshw.2021.12.006 · Cited by 78
Patología vascular: ¿causa o efecto en la enfermedad de Alzheimer?
Rius-Pérez, S., Tormos, A. M., Pérez, S., & Taléns-Visconti, R. (2018) · Neurología · doi:10.1016/j.nrl.2015.07.010 · Cited by 70
“…de LRP1 en los microvasos cerebrales están asociados con la acumulación del A (cid:2) en el cerebro durante el envejeci-miento y durante la EA 47,48 Se ha demostrado también que el LRP1 cerebral se oxida en la EA mediante un mecanismo oxidativo que puede implicar al propio A (cid:2) , lo que…”
The cerebromicrovasculature: A key player in the pathogenesis of Alzheimer's disease
Grammas, P., Yamada, M., & Zlokovic, B. (2002) · Journal of Alzheimer's Disease · doi:10.3233/jad-2002-4311 · Cited by 73
“Down-regulation of vascular LRP-1 correlated with regional A β accumulation in brains of AD [42].”
Terasaki, T., & Ohtsuki, S. (2004) · NeuroRx · doi:10.1602/neurorx.2.1.63 · Cited by 79
“Shibata et al.48 have reported that A 1-40 undergoes efflux from the brain across the BBB, and low-density lipoprotein-related protein (LRP-1) is involved in this efflux process (Table 1).”
BackgroundNagaraja, T. N., Patel, P., Gorski, M., Gorevic, P. D., Patlak, C. S., & Fenstermacher, J. D. (2005) · Cerebrospinal Fluid Research · doi:10.1186/1743-8454-2-5 · Cited by 74
“These observations are indicative of the distribution and tissue injury obtained when agents and tracers are deliberately or accidentally administered into the parenchyma [23,24].”
BackgroundNelson, A. R., Sagare, M. A., Wang, Y., Kisler, K., Zhao, Z., & Zlokovic, B. V. (2020) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2020.00108 · Cited by 73
“…the capillary level (Aldea et al., 2019) this could potentially impact periarterial drainage of Aβ (Diem et al., 2016) and/or its trans-vascular clearance across the BBB (Shibata et al., 2000; Deane et al., 2004; Nelson et al., 2017), or via meningeal lymphatic vessels (Da Mesquita et al., 2018).”
BackgroundInfluentialStorck, S. E., & Pietrzik, C. U. (2017) · Pharmaceutical Research · doi:10.1007/s11095-017-2267-3 · Cited by 79
“the BBB (66,69) or LRP1-mediated degradation in cerebral cells (74,75,78).”
BackgroundInfluentialMadadi, A. K., & Sohn, M. (2024) · Pharmaceuticals · doi:10.3390/ph17081070 · Cited by 84
“While some studies detected LRP1 in mouse brain microvessels, others failed to find it in human brain tissues [257–259].”
ResultTau Proteins Cross the Blood-Brain Barrier
Banks, W. A., Kovac, A., Majerova, P., Bullock, K. M., Shi, M., & Zhang, J. (2016) · Journal of Alzheimer's Disease · doi:10.3233/jad-160542 · Cited by 67
Bres, E. E., & Faissner, A. (2019) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2019.00031 · Cited by 70
“Main component of amyloid plaques found in Alzheimer’s patients Kang et al., 2000; Shibata et al., 2000 Amyloid precursor protein (APP) Integral membrane protein, during its proteolysis the amyloid β peptide is generated Kounnas et al., 1995a; Ulery et al., 2000 Annexin VI Member of the…”
BackgroundAβ immunotherapy for Alzheimer’s disease: effects on apoE and cerebral vasculopathy
Sakai, K., Boche, D., Carare, R., Johnston, D., Holmes, C., Love, S., & Nicoll, J. A. R. (2014) · Acta Neuropathologica · doi:10.1007/s00401-014-1340-9 · Cited by 72
“Secondly, apoE acts as a key molecule to transport Aβ across the blood–brain barrier [42], mediated by low-density lipoprotein receptor-related protein 1 (LRP1) and very low-density lipoprotein receptor (VLDLR) [54].”
Katsouri, L., & Georgopoulos, S. (2011) · PLoS ONE · doi:10.1371/journal.pone.0021880 · Cited by 72
“LRP1 has also been shown to be involved in the clearance of amyloid [36,37,38].”
BackgroundKajiwara, Y., Franciosi, S., Takahashi, N., Krug, L., Schmeidler, J., Taddei, K., Haroutunian, V., Fried, U., Ehrlich, M., Martins, R. N., et al. (2010) · Molecular Neurodegeneration · doi:10.1186/1750-1326-5-1 · Cited by 72
Modulation of the Cannabinoid System: A New Perspective for the Treatment of the Alzheimer’s Disease
Talarico, G., Trebbastoni, A., Bruno, G., & de Lena, C. (2018) · Current Neuropharmacology · doi:10.2174/1570159x16666180702144644 · Cited by 77
Lipids in Amyloid-β Processing, Aggregation, and Toxicity
Morgado, I., & Garvey, M. (2015) · Advances in Experimental Medicine and Biology · doi:10.1007/978-3-319-17344-3_3 · Cited by 71
Lam, M. A., Hemley, S. J., Najafi, E., Vella, N. G. F., Bilston, L. E., & Stoodley, M. A. (2017) · Scientific Reports · doi:10.1038/s41598-017-13455-4 · Cited by 71
Characteristics of Dyshoric Capillary Cerebral Amyloid Angiopathy
Richard, E., Carrano, A., Hoozemans, J. J., van Horssen, J., van Haastert, E. S., Eurelings, L. S., de Vries, H. E., Thal, D. R., Eikelenboom, P., van Gool, W. A., et al. (2010) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0b013e3181fab558 · Cited by 71
The role of inflammatory processes in Alzheimer’s disease
Broussard, G. J., Mytar, J. O., Li, R., & Klapstein, G. J. (2012) · Inflammopharmacology · doi:10.1007/s10787-012-0130-z · Cited by 75
Apolipoprotein C-III is an Amyloid-β-Binding Protein and an Early Marker for Alzheimer's Disease
Shih, Y.-H., Tsai, K.-J., Lee, C.-W., Shiesh, S.-C., Chen, W.-T., Pai, M.-C., & Kuo, Y.-M. (2014) · Journal of Alzheimer's Disease · doi:10.3233/jad-140111 · Cited by 70
“This hypothesis is based on findings of active A transport across the blood-brain barrier through low-density lipoprotein receptor-related protein (LRP) from the CNS into the periphery [17, 18].”
Wyatt, A. R., Yerbury, J. J., Poon, S., Dabbs, R. A., & Wilson, M. R. (2009) · Advances in cancer research · doi:10.1016/s0065-230x(09)04006-8 · Cited by 75
“Evidence from studies in mice suggests that this could be the case; radiolabeled A injected in to the brain of mice is normally rapidly removed, however, coinjection with the LDL family inhibitor RAP, antibodies against LRP-1 or 2-macroglobulin significantly slows its removal (Shibata et al., 2000).”
BackgroundSwaminathan, S. K., Ahlschwede, K. M., Sarma, V., Curran, G. L., Omtri, R. S., Decklever, T., Lowe, V. J., Poduslo, J. F., & Kandimalla, K. K. (2018) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1177/0271678x17709709 · Cited by 67
“Although several pathways may be involved in clearing Ab from the brain, the vascular clearance – mediated by the BBB endothelium, a highly specialized trafficking portal, and pericytes that modulate BBB signaling/ trafficking – is the most predominant.(34) Insulin signaling pathways are shown to be critical for the f…”
CNS-Draining Meningeal Lymphatic Vasculature: Roles, Conundrums and Future Challenges
das Neves, S. P., Delivanoglou, N., & Mesquita, S. D. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.655052 · Cited by 79
“Toxic Aβ species can be removed from the brain interstitium by several mechanisms, including degradation by enzymes (Qiu et al., 1998; Farris et al., 2003; HernandezGuillamon et al., 2015), phagocytosis by microglia and astrocytes (Weldon et al., 1998; Jones et al., 2013), receptormediated excretion across the BBB (Sh…”
BackgroundInfluentialDissecting the Contribution of Vascular Alterations and Aging to Alzheimer’s Disease
Janota, C. S., Lemere, C. A., & Brito, M. A. (2015) · Molecular Neurobiology · doi:10.1007/s12035-015-9319-7 · Cited by 78
“LRP-1 is the major efflux transporter for Aβ across the BBB [107], and in human brain it is abundantly expressed by neurons, astrocytic feet processes, VSMC, pericytes, and, to a lesser extent, by the endothelium.”
BackgroundEvidence for lymphatic Aβ clearance in Alzheimer's transgenic mice
Pappolla, M., Sambamurti, K., Vidal, R., Pacheco-Quinto, J., Poeggeler, B., & Matsubara, E. (2014) · Neurobiology of Disease · doi:10.1016/j.nbd.2014.07.012 · Cited by 69
Inhibition of Aquaporin 4 Decreases Amyloid Aβ40 Drainage Around Cerebral Vessels
Roşu, G. C., Cătălin, B., Bălşeanu, T. A., Mogoantă, L., Mărgăritescu, C., Kumar‐Singh, S., & Pirici, D. N. (2020) · Molecular Neurobiology · doi:10.1007/s12035-020-02044-8 · Cited by 77
“In this direction, a variety of mechanisms have been described that might be able to facilitate the access of IgG in the parenchyma through the blood vessel wall, like for example binding to the neonatal Fc receptor (FcRn) [64], the LRP-1 [65], transferrin, or insulin receptors [66].”
BackgroundGauthier, A., Vassiliou, G., Benoist, F., & McPherson, R. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m212989200 · Cited by 66
Silk Fibroin As an Immobilization Matrix for Sensing Applications
Prakash, N. J., Mane, P. P., George, S. M., & Kandasubramanian, B. (2021) · ACS Biomaterials Science & Engineering · doi:10.1021/acsbiomaterials.1c00080 · Cited by 70
Pahnke, J., Walker, L. C., Scheffler, K., & Krohn, M. (2009) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2009.05.006 · Cited by 66
“Apolipoprotein E is considered to be involved in the RAGE/LRP1 shuffling mechanism (Shibata et al., 2000), and polymorphisms in apolipoprotein E (ApoE) are known to markedly influence the risk of late-onset AD (Saunders (Saunders et al., 1993; Schmechel et al., 1993; Strittmatter et al., 1993a,b;…”
Gaultier, A., Arandjelovic, S., Li, X., Janes, J., Dragojlovic, N., Zhou, G. P., Dolkas, J., Myers, R. R., Gonias, S. L., & Campana, W. M. (2008) · Journal of Clinical Investigation · doi:10.1172/jci32371 · Cited by 63
Tamboli, I. Y., Prager, K., Thal, D. R., Thelen, K. M., Dewachter, I., Pietrzik, C. U., St. George-Hyslop, P., Sisodia, S. S., De Strooper, B., Heneka, M. T., et al. (2008) · The Journal of Neuroscience · doi:10.1523/jneurosci.2635-08.2008 · Cited by 68
“Because apo E together with lipoprotein receptors also mediate A clearance within the brain and through the blood– brain barrier (Kang et al., 2000; Shibata et al., 2000; Van Uden et al., 2002), impaired -secretase function might affect A clearance.”
BackgroundAPP Processing and the APP-KPI Domain Involvement in the Amyloid Cascade
Menéndez-González, M., Pérez-Pinera, P., Martínez-Rivera, M., Calatayud, M. T., & Blázquez Menes, B. (2005) · Neurodegenerative Diseases · doi:10.1159/000092315 · Cited by 59
“This mechanism is age dependent, and lower clearance rates in older animals correlate with decreased vascular levels of LRP [”
BackgroundHan, S.-H., Park, J.-C., & Mook-Jung, I. (2016) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2015.12.004 · Cited by 67
Metadata
- Authors
- Shibata, M., Yamada, S., Kumar, S. R., Calero, M., Bading, J., Frangione, B., Holtzman, D. M., Miller, C. A., Strickland, D. K., Ghiso, J., & Zlokovic, B. V.
- Affiliations
- University of Southern California (US)
- NYU Langone Health (US)
- Washington University in St. Louis (US)
- American Red Cross (US)
- University of Rochester Medicine (US)
- ORCID
- Venue
- Journal of Clinical Investigation
- Published
- 2000-12-15
- Volume
- 106
- Issue
- 12
- Pages
- 1489-1499
- ISSN
- 0021-9738 (ISSN-L)
- PMC
- PMC387254
- OpenAlex
- W1997822484
- Cited by
- 1,413
- References
- 76
- Citations by year
- 2026: 38 · 2025: 60 · 2024: 58 · 2023: 59 · 2022: 57 · 2021: 75 · 2020: 85 · 2019: 73 · 2018: 52 · 2017: 67 · 2016: 64 · 2015: 56 · 2014: 60 · 2013: 62 · 2012: 60
- FWCI
- 15.51
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Journal of Clinical Investigation (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health (5p01ag016223-04)
- National Institute on Aging (R37AG005891, R01AG013956, P50AG005142, AG16223, R37AG013956, AG05891)
- National Heart, Lung, and Blood Institute (R01HL050784)
- National Institute of Neurological Disorders and Stroke (NS 33466, R01NS038777)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Life Sciences › Neuroscience › Neurology › Barrier Structure and Function Studies
- Health Sciences › Medicine › Oncology › Drug Transport and Resistance Mechanisms
- Keywords
- Aβ40, Alzheimer's disease, blood-brain barrier, LDL receptor-related protein 1, receptor-associated protein, alpha2-macroglobulin, apolipoprotein E, amyloid-beta clearance, efflux transport, cerebral microvasculature, amyloid-beta deposition
- MeSH terms
- Aging, alpha-Macroglobulins, Alzheimer Disease, Amino Acid Sequence, Animals, Apolipoproteins E, Biological Transport, Blood-Brain Barrier, Brain, Catheterization, Genotype, Half-Life, Humans, Immunohistochemistry, Inulin, Iodine Radioisotopes, Kinetics, Male, Mice, Inbred C57BL, Molecular Sequence Data, Peptide Fragments, Receptors, Immunologic, Amyloid beta-Peptides, Mice, Knockout, Low Density Lipoprotein Receptor-Related Protein-1, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-11-09, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-11-09 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.






